Tempest Therapeutics Inc. (TPST)

NasdaqCM: TPST · Real-Time Price · USD

1.13

+0.12 (11.88%)

At close: Aug 17, 2026, 8:00 PM

1.13

+0.00%

After-hours: 7:41 PM

11.88% (1D)

No data available

Bid	0.84
Market Cap	18.06M
Revenue (ttm)	n/a
Net Income (ttm)	-40.47M
Beta	n/a
EPS (ttm)	-4.08
PE Ratio (ttm)	n/a
Forward PE	-0.93
P/B (ttm)	19.82
P/S (ttm)	n/a
Earnings Date	Nov 5, 2026

Ask	1.34
Volume	811,440
Avg. Volume (20D)	193,932
Open	1.09
Previous Close	1.01
Day's Range	1.04 - 1.17
52-Week Range	0.84 - 12.23
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About TPST

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 12, 2012

Employees 4

Stock Exchange NasdaqCM

Ticker Symbol TPST

Website https://www.tempesttx.com

Full Company Profile

Financial Performance

In 2025, Tempest Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -26.26M, a decrease of -37.24%.

Financial Statements